Aethlon is seeking an FDA Humanitarian Use Device exemption for its Hemopurifier, a bio-filtration system that could be used as an Ebola treatment option.
A first-in-class device, the Hemopurifier was developed for single-use virus removal and to shed glycoproteins from circulatory systems of infected individuals. The system specifically targets antiviral drug resistance, having the potential to be a first-line defense against Ebola, HIV, hepatitis C and other viruses unable to be treated with drug therapy, the San Diego, Calif., company claims.
A clinical study is underway in India to measure the system’s ability to accelerate viral load depletion when used in conjunction with hepatitis C standard of care drug therapy.
In vitro studies demonstrate the Hemopurifier can capture exosomes underlying various cancers, such as colorectal, lymphoma, melanoma, ovarian and breast, the company claims.
To that end, Aethlon has partnered with the Sarcoma Oncology Center in Santa Monica for a 25-patient clinical trial studying the device’s ex vivo efficacy in removing immunosuppressive exosomes from cancer patients. — Jason Scott